The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial
Nadine Rouphael(Emory University), Wendy Nesheim(Emory University), Elena V. Vassilieva(Emory University), Srilatha Edupuganti(Emory University), Tianwei Yu(Emory University), Devin V. McAllister(Georgia Institute of Technology), Natalie J. Thornburg(Oak Ridge Associated Universities), Sarah Kabbani(Centers for Disease Control and Prevention), Mark R. Prausnitz(Georgia Institute of Technology), Winston Pewin(Georgia Institute of Technology), Paula M. Frew(Emory University), Michele Paine(HOPE Clinic), Sheila Heeke, Ioanna Skountzou(Emory University), Mark J. Mulligan(New York University), Richard W. Compans(Emory University), Haripriya Kalluri(Georgia Institute of Technology), Lilin Lai(Emory Healthcare), Colleen F. Kelley(Emory University), Regina Mosley(Emory University), Allison Beck, Sébastien Henry(Georgia Institute of Technology)
Cited by 423
Related Papers
Transdermal drug delivery
|Nature Biotechnology|2008|3.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847
Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
|Emerging infectious diseases|2020|628
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|540